文献速递消化系统肿瘤

SCOT研究最终结果:结直肠癌辅助化疗3个月对比6个月

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
PubMed 文献 · J Clin Oncol · 2026-01-09

SCOT研究是一项国际随机III期非劣效性试验,纳入高危II期和III期结直肠癌患者,比较3个月与6个月奥沙利铂-氟尿嘧啶辅助化疗。中位随访113个月,5年总生存率两组均为82.4%(HR 0.96,95%CI 0.8-1.07),证明3个月治疗总生存非劣效。疗效 duration 效应与方案相关,CAPOX非劣效而FOLFOX未显示非劣效。

要点

  • 3个月辅助化疗总生存非劣效于6个月,5年OS率均为82.4%。
  • CAPOX方案3个月非劣效,FOLFOX方案未显示非劣效。
  • 直肠癌亚组(1087例)也显示3个月治疗总生存非劣效。

核心结论

  • SCOT研究证明3个月辅助化疗总生存非劣效于6个月,推荐多数患者采用3个月治疗。

研究设计与样本

  • 国际随机III期非劣效性试验,纳入高危II期和III期结直肠癌患者,1:1随机分配接受3或6个月CAPOX或FOLFOX方案化疗。

主要发现

  • 中位随访113个月,1255例总生存事件,3个月与6个月组5年OS均为82.4%(HR 0.96,95%CI 0.8-1.07)。
  • 直肠癌亚组1087例也显示3个月治疗总生存非劣效。
  • duration 效应与方案相关:CAPOX非劣效,FOLFOX未显示非劣效。

关键数值与推荐

  • 5年OS率:3个月组82.4%,6个月组82.4%,HR 0.96(95%CI 0.8-1.07)。

临床怎么用

  • 对于大多数高危II期和III期结直肠癌患者,可推荐3个月辅助化疗以降低神经毒性并改善生活质量。
  • 选择CAPOX方案时3个月非劣效证据充分,FOLFOX方案仍需谨慎考虑6个月疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Iveson T, Saunders MP, Kelly C, et al. Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. J Clin Oncol. 2026. PMID: 41512219. doi:10.1200/JCO-25-00621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。